Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael Untch"'
Autor:
W. Fraser Symmans, Mehra Golshan, Kristi McIntyre, Mark D. McKee, David Maag, Sibylle Loibl, Michael Untch, Charles E. Geyer, Joyce O'Shaughnessy, Otto Metzger Filho, Danielle Sullivan, Hope S. Rugo, Gunter von Minckwitz, Jose Juan Ponce Lorenzo, William M. Sikov, Jens Huober, Xuan Liu, Priya Rastogi, Norman Wolmark
Publikováno v:
LANCET ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Background Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelih
Autor:
Joern Hilfrich, Sherko Kümmel, F Khandan, Peter A. Fasching, Christian Jackisch, Stefan Paepke, Dirk Michael Zahm, Keyur Mehta, Hans Tesch, Jens Huober, SD Costa, Peter Klare, Bruno Valentin Sinn, Claus Hanusch, Christoph Salat, Jens Uwe Blohmer, Valentina Nekljudova, Gunter von Minckwitz, Sibylle Loibl, Mahdi Rezai, Bernd Gerber, Andreas Schneeweiss, Michael Untch, Holger Eidtmann, Carsten Denkert, Knut Engels
Publikováno v:
The Lancet. Oncology. 15(7)
Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore
Autor:
Ingo Bauerfeind, Gunter von Minckwitz, Michael Untch, Tanja Fehm, Sabine Schmatloch, Maik Hausschild, Annette Lebeau, Cornelia Liedtke, P Schrenk, Thorsten Kuehn, Gisela Helms, Valentina Nekljudova, Barbara Fleige, Annette Staebler
Publikováno v:
The Lancet. Oncology. 14(7)
Summary Background The optimum timing of sentinel-lymph-node biopsy for breast cancer patients treated with neoadjuvant chemotherapy is uncertain. The SENTINA (SENTinel NeoAdjuvant) study was designed to evaluate a specific algorithm for timing of a
Autor:
Vladimir Semiglazov, Andrea Veronesi, Richard D. Gelber, Martine Piccart-Gebhart, S. Muehlbauer, Ian E. Smith, Luca Gianni, Urania Dafni, Jose Luiz Pedrini, Evandro de Azambuja, David Cameron, Christian Jackisch, Cesar Mendiola, Anna Pluzanska, Marion Procter, José Baselga, Aron Goldhirsch, Eduard Vrdoljak, Max S. Mano, Kathleen I. Pritchard, George Skiadopoulos, Richard Bell, Michael J Eckart, Michael Untch, Zhenzhou Shen
Publikováno v:
The Lancet. Oncology. 12(3)
Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess disease-free survival and overall sur